Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study

Similar documents
Mortality Reduction Associated With β-adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes

Statin Therapy Reduces Future Risk of Lower- Limb Amputation in Patients With Diabetes and Peripheral Artery Disease

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Diabetic Dyslipidemia

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Update on CVD and Microvascular Complications in T2D

Seung-Hwan Lee, M.D., Ph.D.

Phototherapy and Seizures: Should We Change Practice?

Race Original cohort Clean cohort HR 95%CI P HR 95%CI P. <8.5 White Black

Lipid Management 2013 Statin Benefit Groups

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

egfr > 50 (n = 13,916)

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

Supplementary Online Content

The American Diabetes Association estimates

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Rhinovirus in Febrile Infants and Risk of Bacterial Infection

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Supplementary Online Content

Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

B. Patient has not reached the percentage reduction goal with statin therapy

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Welcome and Introduction

Cholesterol Management Roy Gandolfi, MD

Pathophysiology of Lipid Disorders

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Clinical Study Synopsis

The Diabetes Link to Heart Disease

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Dyslipedemia New Guidelines

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

Diabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER

Use of Subgroups to Rescue a Trial or Improve Benefit-Risk

Diabetes Mellitus: A Cardiovascular Disease

ATP IV: Predicting Guideline Updates

Cardiovascular Complications of Diabetes

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus

Supplementary Online Content

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Magnetic resonance imaging, image analysis:visual scoring of white matter

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

Cardiovascular Management of a Patient with Diabetes

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Supplementary Appendix

The CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors

Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion

How to Reduce Residual Risk in Primary Prevention

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Kidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

Approach to Dyslipidemia among diabetic patients

CVD Prevention, Who to Consider

Diabetes and the Heart

New Guidelines in Dyslipidemia Management

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

MOLINA HEALTHCARE OF CALIFORNIA

DIABETES MEASURES GROUP OVERVIEW

Reconstruing Codependency Using Self-in- Relation Theory: A Feminist Perspective

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Contemporary management of Dyslipidemia

Review of guidelines for management of dyslipidemia in diabetic patients

Secondary analyses of HSE data and linked health outcomes - an overview of work in progress. UCL (University College London)

Jennifer S. Lee, 1,2 Po-Yin Chang, 1 Ying Zhang, 3 Jorge R. Kizer, 4 Lyle G. Best, 5 and Barbara V. Howard 6 OBJECTIVE RESEARCH DESIGN AND METHODS

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total

Improved control for confounding using propensity scores and instrumental variables?

Increasing Campylobacter Infections, Outbreaks, and Antimicrobial Resistance in the United States,

Ο ρόλος των τριγλυκεριδίων στην παθογένεια των μικροαγγειοπαθητικών επιπλοκών του σακχαρώδη διαβήτη

RECOGNITION OF THE METABOLIC SYNDROME

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Familial hypercholesterolaemia in children and adolescents

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus

Transcription:

1/5 Triglyceride and HDL-C Dyslipidemia and Risks of Coronary Heart Disease and Ischemic Stroke by Glycemic Dysregulation Status: The Strong Heart Study Jennifer S. Lee, Po-Yin Chang, Ying Zhang, Jorge R. Kizer, Lyle G. Best, Barbara V. Howard Diabetes Care 2017 Jan; dc161958. https://doi.org/10.2337/dc16-1958 Previous Next Article Info & Metrics PDF Abstract OBJECTIVE High triglyceride (TG) levels and low HDL cholesterol (HDL-C) levels are risk factors for cardiovascular disease. It is unclear whether this relationship depends on glycemic dysregulation, sex, or LDL cholesterol (LDL-C) level. RESEARCH DESIGN AND METHODS We studied 3,216 participants (40% men, 41% with diabetes) who were free of cardiovascular disease at baseline in a community-based, prospective cohort of American Indians (median follow-up 17.7 years). Cox models estimated hazard ratios (HRs) and 95% CIs for incident ischemic stroke and coronary heart disease (CHD) in relation to combined TG and HDL-C status, where a fasting TG level 150 mg/dl was high and a fasting HDL-C level <40 mg/dl for men (<50 mg/dl for women) was low. Models included age, sex, BMI, smoking, diabetes, fasting LDL-C level, antihypertensive medications, physical activity, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio. RESULTS Participants with high TG and low HDL levels had a 1.32-fold greater HR (95% CI 1.06 1.64) for CHD than those with normal TG and normal HDL levels. It was observed in participants with diabetes, but not in those without diabetes, that high TG plus low HDL levels were associated with a 1.54-fold greater HR (95% CI 1.15 2.06) for CHD (P value for interaction = 0.003) and a 2.13-fold greater HR (95% CI 1.06 4.29) for stroke (P value for interaction = 0.060). High TG and low HDL level was associated with CHD risk in participants with a LDL-C level of 130 mg/dl, but this was not observed in those participants with lower LDL-C levels. Sex did not appear to modify these associations.

2/5 CONCLUSIONS Adults with both high TG and low HDL-C, particularly those with diabetes, have increased risks of incident CHD and stroke. In particular, those with an LDL-C level 130 mg/dl may have an increased risk of incident stroke. Received September 10, 2016. Accepted January 2, 2017. 2017 by the American Diabetes Association. http://www.diabetesjournals.org/content/license Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. Log in using your username and password Username Password Log in Forgot your user name or password? Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00 Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired. We recommend Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study. Brian C Callaghan et al., Diabetes Care, 2011 Does elevated plasma triglyceride level independently predict impaired fasting glucose?: the Multi-Ethnic Study of Atherosclerosis (MESA). Susan X Lin et al., Diabetes Care, 2012 The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses. Henry N Ginsberg, Diabetes Care, 2011 Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Sander J Robins et al., Diabetes Care, 2003 Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Todd M Brown et al., Diabetes Care, 2013 Lipid Levels Have Contrasting Effects on Coronary Artery Disease and Diabetes Association of Lipids and Heart Disease in Contemporary Studies PracticeUpdate, 2015 Is Isolated Low HDL a Cardiovascular Risk Factor? Fenofibrate Therapy Reduces Long-Term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes PracticeUpdate, 2017 The Association of Type 2 Diabetes With Lipoproteins, Insulin Resistance, and Rosuvastatin

3/5 Powered by Previous Next Back to top Current Issue February 2017, 40(2) Table of Contents Table of Contents (PDF) About the Cover Index by Author Masthead (PDF) Search this issue Sign up to receive current issue alerts Article Alerts Email Article Citation Tools Share Request Permissions Tweet 1 0

4/5 Related Articles No related articles found. PubMed Google Scholar Cited By... More in this TOC Section Similar Articles Navigate Current Issue Online Ahead of Print Archives Submit Subscribe E-mail Alerts RSS Feeds

5/5 More Information About the Journal Instructions for Authors Journal Policies Reprints and Permissions Advertising Privacy Policy: ADA Journals Copyright Notice/Public Access Policy Contact Us Other ADA Resources Diabetes Clinical Diabetes Diabetes Spectrum BMJ Open - Diabetes Research & Care Standards of Medical Care in Diabetes Scientific Sessions Abstracts Professional Books Diabetes Forecast DiabetesJournals.org patientinform Diabetes Core Update Diabetes Journals Mobile ADA's DiabetesPro ADA Member Directory Diabetes.org 2017 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.